請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45060
標題: | 小兒急性B淋巴細胞白血病中轉錄因子PAX5變異之調查 Investigating the Variation of Transcription Factor PAX5 in Childhood B-Acute Lymphoblastic Leukemia |
作者: | Yen-Ju Chen 陳衍儒 |
指導教授: | 胡忠怡(Chung-Yi Hu) |
關鍵字: | 小兒急性B淋巴細胞白血病,PAX5,PAX5 mRNA表現量,PAX5蛋白表現量,失去異合性, acute B-lymphoid leukemia (B-ALL),PAX5 (paired box 5),PAX5 mRNA expression,PAX5 protein expression,loss of heterozygosity (LOH), |
出版年 : | 2010 |
學位: | 碩士 |
摘要: | PAX5 (Paired box 5)基因屬PAX基因家族的一員,表現於中樞神經及造血系統。PAX5蛋白N端會辨識目標基因之專一性DNA序列,C端會吸引其他轉錄相關蛋白,調控基因表現,並決定B細胞發育(B-cell commitment)。小兒急性淋巴性白血病(childhood acute lymphoid leukemia, childhood ALL)為淋巴系細胞發生癌變增生,使骨髓中的白血球失去正常細胞分化能力,影響正常造血細胞生長及功能的惡性腫瘤。在前人大規模調查研究中發現,小兒與成人B細胞ALL病人中,有近30%的病人在PAX5基因產生單一或雙對偶基因缺失、染色體轉位或點突變,暗示PAX5在B-ALL成病過程中,可能扮演重要角色。本研究希望了解PAX5在B細胞淋巴性白血病血癌細胞中表現的情形,解析PAX5表現變化與PAX5基因失去異合性(loss of heterozygosity, LOH)的關聯性,探討PAX5表現變異在B-ALL病患中是否具有分子特徵或臨床預後價值。
本研究針對採自25名小兒B-ALL患者之白血病細胞及3位正常B細胞對照組進行PAX5 mRNA表現量差異與臨床資料之關聯性分析,並進一步分析部分病人的PAX5蛋白表現量差異,及此差異是否源自PAX5 DNA之變異。結果顯示,雖未達統計上顯著差異,B-ALL白血病細胞內PAX5 mRNA表現普遍偏低(median (25%-75%), B-ALL:0.4 (0-0.9), Normal:0.9 (0.9-1), p=0.1438),半數以上B-ALL病人白血病細胞的PAX5 mRNA表現量低於正常B細胞對照組的一半以下。進一步分析PAX5 mRNA表現量與B-ALL細胞同時表現non-B marker數目之關聯性,雖未達統計上顯著差異,但可看到白血病細胞PAX5表現量較低,與其帶有較多non-B markers有關聯。此外,白血病細胞較正常B細胞擁有較多種長度變異片段。本研究亦分析7位B-ALL病人的白血病細胞PAX5蛋白表現量,發現其中4例PAX5蛋白表現量較低,3例表現量與正常B細胞對照組相似,且PAX5蛋白表現量趨勢與mRNA大致相同。另外利用微衛星標記分析6位B-ALL病人白血病細胞及緩解時期的PAX5 DNA刪除情形,3例為LOH,1例為無改變的異合子;奇怪的是,PAX5 DNA刪除情形與PAX5 mRNA表現量並不一致。綜合以上結果,顯示PAX5 mRNA、蛋白表現量差異,與PAX5 DNA是否發生LOH無直接關聯。結論: 1. 小兒急性B淋巴細胞白血病病人的PAX5基因表現量普遍較低。2. 部份B-ALL病人帶有較多的C端變異片段,包括影響PAX5蛋白質transactivation能力的Δ7/8片段。3. 部分病人的PAX5蛋白質表現量有顯著下降,但與PAX5基因劑量降低無直接相關。因此PAX5基因在DNA轉錄為RNA過程中,除了基因劑量外,或許仍有其他機制參與調控RNA表現。 PAX5 (Paired box 5), a member of PAX gene family, is expressed in the central nervous and the hematopoietic systems and is known to play an important role in B cell commitment. Childhood acute lymphoid leukemia (ALL) is a malignant disease resulting from uncontrolled proliferation of lymphoid progenitors. In previous large-scaled study, the PAX5 gene was the most frequent target of somatic mutation, being altered in about 30% in both pediatric and adult patients with B-ALL. However, whether PAX5 mutation plays an important role in B-ALL leukemogenesis remains uncharacterized. In this study, we intend to investigate the molecular or clinical characteristics of PAX5 expression alteration in B-ALL. The RNA and protein expression, DNA status (loss of heterozygosity, LOH) of PAX5 gene, as well as clinical data were investigated in 25 diagnostic bone marrow samples obtained from childhood B-ALL patients. Peripheral blood mature B cells obtained from 3 healthy subjects were used as control. Decreased PAX5 mRNA expression was noted in 14 out of 25 leukemic samples as compared to normal mature B cells (median (25%-75%), ALL: 0.4 (0-0.9), Normal: 0.9 (0.9-1), p=0.1438). Although it was not statistically significant, it revealed that the leukemic cells with decreased level of PAX5 mRNA expression tend to carry more non-B markers. There were more mRNAs with variant sizes in leukemic cells than in normal mature B cells. PAX5 protein level was also investigated in the leukemic cells of 7 B-ALL patients. Four showed decreased PAX5 expression and the other 3 were of comparable PAX5 level as compared to normal mature B cells. We also investigated LOH of PAX5 locus in 6 paired-samples (leukemic bone marrow cells and remission peripheral blood cells as normal reference) from B-ALL patients via short tandem repeat analysis. Three showed LOH and one remained heterozygous. The DNA status was not correlated with mRNA expression level. In summary, the trend of decreased PAX5 protein expression was parallel to that of PAX5 mRNA expression level, but is not correlated with DNA status. The results indicate that: 1. PAX5 mRNA expression is generally decreased in B-ALL patients; 2. There were more PAX5 C-terminal variant forms present in B-ALL leukemic samples, including transcript without exons 7 and 8, which may influence trans-activating ability of PAX5; 3. Significantly decreased protein level in 14 out of 25 B-ALL patients reveals the association in B-ALL and decreased PAX5 expression; 4. Besides the gene dosage, some other factors could regulate PAX5 transcription through mechanisms awaited further studies. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45060 |
全文授權: | 有償授權 |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 1.47 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。